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Abstract
Aims: Mesenchymal stromal cells (MSCs) are heterogeneous cells from adult tissues that are able to differ-
entiate in vitro into adipocytes, osteoblasts, or chondrocytes. Such cells are widely studied in regenerative
medicine. However, the success of cellular therapy depends on the cell survival. Heme oxygenase-1 (HO-1,
encoded by the Hmox1 gene), an enzyme converting heme to biliverdin, carbon monoxide, and Fe2+, is
cytoprotective and can affect stem cell performance. Therefore, our study aimed at assessing whether Hmox1 is
critical for survival and functions of murine bone marrow MSCs.
Results: Both MSC Hmox1+/+ and Hmox1-/- showed similar phenotype, differentiation capacities, and production
of cytokines or growth factors. Hmox1+/+ and Hmox1-/- cells showed similar survival in response to 50lmol/L
hemin even in increased glucose concentration, conditions that were unfavorable for Hmox1-/- bone marrow-
derived proangiogenic cells (BDMC). Hmox1+/+ MSCs but not fibroblasts retained low ROS levels even after
prolonged incubation with 50lmol/L hemin, although both cell types have a comparable Hmox1 expression and
similarly increase its levels in response to hemin. MSCs Hmox1-/- treated with hemin efficiently induced ex-
pression of a vast panel of antioxidant genes, especially enzymes of the glutathione pathway.
Innovation and Conclusion: Hmox1 overexpression is a popular strategy to enhance viability and perfor-
mance of MSCs after the transplantation. However, murine MSCs Hmox1-/- do not differ from wild-type
MSCs in phenotype and functions. MSC Hmox1-/- show better resistance to hemin than fibroblasts and
BDMCs and rapidly react to the stress by upregulation of quintessential genes in antioxidant response.
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Introduction
Mesenchymal stromal cells (MSCs), also known asmesenchymal stem cells, or multipotent stromal cells
are a heterogeneous population of connective tissue cells that
contains osteoblast and adipocyte progenitors, fibroblasts,
and smooth muscle cells (5). In vitro criteria for humanMSCs
include adherence to the plastic in standard culture condi-
tions, differentiation in vitro to adipocytes, osteoblasts,
and chondrocytes (9). MSCs should express CD73, CD90,
and CD105 markers but not CD45, CD34, CD14, CD11b,
CD79a, CD19, and HLA-DR (9). MSCs were further
identified, also in vivo, by CD271 and CD106 (human)
(33), CD146 (44), nestin (34), Sca-1 (mouse) and PDGFRa
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(36), leptin receptor LepR (8, 67), or high expression of
CXCL12 (41).
MSCs were shown to be immune evasive or immunomod-
ulatory, depending on the microenvironment (2). The mecha-
nism of immunosuppression is complex and involves many
factors, that is, prostaglandin E2, nitric oxide, and TGFb (39).
AlthoughMSCs are commonly believed to deal with oxidative
stress efficiently (55), the biggest obstacle to the therapeutic use
of MSCs is their poor survival and engraftment after the
transplantation (11). Therefore, many studies focus on the en-
hancement of their antioxidant activity with overexpression of
various genes, for example, Hmox1 (54, 63).
Heme oxygenase-1 (HO-1, encoded by the HMOX1 gene)
is an enzyme degrading heme to carbon monoxide (CO),
biliverdin, and Fe2+ ions. Due to its enzymatic activity, heme
oxygenase-1 influences cell survival, resistance to the oxi-
dative stress, and angiogenesis (10). We have recently shown
that proangiogenic cells isolated from the bone marrow of
Hmox1 knock-out mice present impaired proliferation, mi-
gration, and formation of capillaries (16). What is more,
overexpression of heme oxygenase-1 can lead to the block of
differentiation, that is, in myoblasts (27).
Rat MSCs transfected with the plasmid coding for human
heme oxygenase-1 showed decreased apoptosis in hypoxia and
higher resistance to H2O2 (54). In our hands, pig bone marrow-
derived cells transduced with adenoviral vectors encoding
heme oxygenase-1 (AdHO1) were characterized by better an-
giogenic activity in vitro and improved left ventricular ejection
fraction 30min after infarction in pigs (63). Treatment with
cobalt protoporphyrin IX (CoPP), heme oxygenase-1 activator,
enhanced proliferation of human mesenchymal stem cells and
production of VEGF; whereas tin protoporphyrin IX (SnPP),
heme oxygenase-1 inhibitor, had an opposite influence (20).
Further, CoPP-treated MSCs accelerated wound healing in a
xenogeneic model of diabetic mice (20).
Modulation of heme oxygenase-1 activity with SnPP in
human MSCs affected their ability to inhibit T cell prolifera-
tion in vitro. Interestingly, the effect of SnPPwas not observed
in rat MSCs, and T cell proliferation was restored only when
concomitant treatment of nitric oxide synthase 2 was used (7).
Moreover, heme oxygenase inhibition decreased the ability of
MSCs to induce Tr1 and Th3 regulatory cells and to elevate
levels of IL-10 and TGFb, respectively. MSCs preconditioned
with a mixed lymphocyte reaction showed decreased HO-1
levels as well as immunomodulatory activity (37).
Finally, the effect of heme oxygenase-1 on MSC differ-
entiation to adipocytes and osteoblasts was also studied.
Abraham and co-workers showed in the series of publications
that enhanced expression of HO-1 in MSCs results in im-
proved differentiation to osteoblasts, whereas its inhibition
promotes adipogenesis (3, 56–59). On the other hand, Zarjou
et al. reported no differences in differentiation potential
between MSC Hmox1+/+ and Hmox1-/- (66). Also in other
studies, overexpression of heme oxygenase-1 in MSCs did
not affect their differentiation (18, 68).
Data on the influence of heme oxygenase-1 on MSCs are
often contradictory. Conjointly, copper or tin protoporphyrins
were used in many studies to modulate HO-1 activity, although
they were shown to have many heme oxygenase-independent
effects in various cell types (17, 23). MSCs are essential for the
proper function of stem cell niches in bonemarrow, and lack of
heme oxygenase-1 was shown to potently affect other bone
marrow-derived cells, that is, pro-angiogenic cells (PACs) (16).
Therefore, we decided to characterize murine bone marrow-
derived MSCs lacking the functional Hmox1 gene, with the
focus on their response to oxidative stress.
Results
Hmox1+/+ or Hmox1-/- bone marrow MSCs show
similar phenotype and differentiation
First, we compared the phenotypes of murine bone marrow
stromal cells Hmox1+/+ or Hmox1-/- in culture by using flow
cytometry. Regardless of the genotype, 60% of the cells in
culture were CD45-CD31- (data not shown). Therefore, cells
used for all the experiments were purified from the remaining
CD45+ fraction with MACS sorting. Obtained cells lacked
expression of endothelial markers CD31 and CD34, whereas
CD117 (c-kit) was expressed only on a small sub-fraction of
cells (Fig. 1A). Isolated MSCs expressed positive markers
that were attributed to the mesenchymal stem/stromal cells,
that is, CD29, CD90, CD105, Ly-6A/E (Sca-1) (Fig. 1B), and
CD140a (PDGFRa) (Fig. 1C, D). Hmox1-/- bone marrow-
derived PACs had impaired proliferation (16). However, the
proliferation of MSC Hmox1+/+ or Hmox1-/- was similar,
even when cells were grown under stress conditions in high
glucose concentration (Fig. 2A).
Further, bone marrow stromal cells isolated from long
bones of mice Hmox1+/+ or Hmox1-/- formed similar num-
bers of colonies that consisted of fibroblastoid cells (Fig. 2B)
or cells able to be differentiated to osteoblasts (Fig. 2C).
MSCs were shown to differentiate into adipocytes, osteo-
blasts, and chondrocytes (6). Both Hmox1+/+ and Hmox1-/-
MSCs differentiated into osteoblasts and adipocytes, which
were evidenced with staining for osteopontin or Fabp4, re-
spectively (Supplementary Fig. S1A, B; Supplementary Data
are available online at www.liebertpub.com/ars).
Because HO-1 was suggested to play a crucial role in the
regulation of MSC adipogenesis (59), we focused on the ef-
fects of Hmox1 knockout on the genes associated with lipid
metabolism. Interestingly, differentiation of murine bone
marrow MSCs to adipocytes induced similar changes in the
gene expression in both Hmox1+/+ and Hmox1-/- cells
(Supplementary Fig. S1C).
However, Hmox1+/+ MSCs were the only ones that in-
creased expression of miR-21-5p, the microRNA that, via
TGFb signaling, regulates adipogenesis (26) (Supplementary
Innovation
Enhancement of stem and progenitor cells antioxidant
capacity is the aim of many studies focusing on the cel-
lular therapies. Many of such strategies propose the
overexpression of Hmox1 as a protection against cell
stress. For the first time, this article shows that mesen-
chymal stromal cells (MSCs) lacking Hmox1 can more
efficiently than other cells deal with oxidative stress in-
duced with hemin, using the mechanism involving the
upregulation of glutathione pathway. High resistance to
stress and unique ability to activate antioxidant response
suggest that MSC may not need additional protection by
Hmox1 overexpression.
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Fig. S1D). Levels of other tested microRNAs associated with
adipogenesis, namely miR-31-5p, miR-150-5p, miR-301a-
5p, miR-378a-3p, or miR-378a-5p, remained unchanged in
cells of both genotypes (Supplementary Fig. S1E–I). Further,
basal expression of all tested microRNAs, including miR-21-
5p, which increased during adipocyte differentiation only in
Hmox1+/+ cells, was similar in MSC Hmox1+/+ and Hmox1-/-
(data not shown).
Effects of changed expression of HMOX1 in human MSCs
on the adipogenesis or osteogenesis were stronger when cells
were cultured in high glucose concentration (3). Therefore,
we tested markers of adipogenesis in MSC Hmox1+/+ or
Hmox1-/- differentiated in low or high glucose concentration.
Interestingly, adipogenic differentiation of murine bone
marrow-derived Hmox1+/+ or Hmox1-/- MSCs did not
change when cells were cultured under high glucose con-
ditions. Both Hmox1+/+ and Hmox1-/- MSCs upregulated
fatty acid-binding protein 4—a marker of adipocyte dif-
ferentiation (Fig. 2D).
MSCs were shown to be precursors of fibroblasts and
myofibroblasts and, therefore, contribute to the tumor stroma
(35) or development of fibrosis (30). Heme oxygenase-1 can
affect both tumor microenvironment (62) and kidney fibrosis
(47). Therefore, we investigated whether the lack of Hmox1
gene in MSCs may influence their ability to form myofibro-
blasts. Hmox1+/+ and Hmox1-/- MSCs were differentiated to
myofibroblasts with TGFb1 treatment for 6 days. Cells
changed their morphology (Supplementary Fig. S1J) and
upregulated a-smooth muscle actin (Acta2) (Fig. 2E). Of
note, upregulation of Acta2 was lower in myofibroblasts
derived from Hmox1-/- cells.
Transcript levels of fibroblast-specific protein 1 (Fsp1)
(Fig. 2F) tended to decrease in Hmox1+/+ and Hmox1-/-
MSCs; however, this trend reached significance only in
FIG. 1. MSC Hmox11/1 or Hmox12/2 have similar phenotype. Expression of MSC positive markers CD29, CD90,
CD105, and Sca-1 (A), MSC negative markers CD31, CD34, and ckit in Hmox1+/+ or Hmox1-/- MSCs (B). Phenotype of
nonsorted bone marrow stromal cells in passage 4: fraction of CD45-CD31- cells in culture (C), fraction of Sca-
1+CD140a+ cells within CD45-CD31- population (D), or Sca-1+CD140a+CD105+ cells within CD45-CD31- population
in Hmox1+/+ or Hmox1-/- cells. (C, D, N = 9–10). MSCs, mesenchymal stromal cells.
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Hmox1-/- cells. To summarize, we show here that MSCs,
regardless of the heme oxygenase-1, show similar phenotype
and differentiation ability, even in stress conditions.
Lack of Hmox1 does not change MSCs
immunomodulatory activity or production of cytokines
Akiyama et al. showed thatMSCs injected intravenously can
decrease numbers of circulating CD3+ and increase T cell ap-
optosis (1).Mougiakakos et al. suggested that inhibition ofHO-
1 activity can decrease MSCs ability to induce T regulatory
cells (37). Therefore, to test the effect of complete knock-out
of Hmox1 on immunomodulatory activity of MSCs, we in-
jected wild-type C57Bl6·FVB mice with MSC Hmox1+/+ or
Hmox1-/- and analyzed apoptosis and activation of T cells.
Numbers of circulating CD3+ T cells did not change in mice
injected with MSCs (Fig. 3A). However, numbers of apoptotic
Annexin V+ CD3+ cells tended to increase after the MSC in-
jection, but this trend did not reach statistical significance
(Fig. 3B). Injection of MSC Hmox1+/+ or Hmox1-/- did not
affect the numbers as well of activated CD3+CD4+CD25high T
cells (Fig. 3C). In vitro, primary murine CD3+ T cells co-
cultured with MSC Hmox1+/+ or Hmox1-/- showed a similar
cell cycle (Supplementary Fig. S2A–C), percentage of Ki67+
cells (Supplementary Fig. S2D) and annexin V+ cells (Sup-
plementary Fig. S2E).
Further, lack of the functional Hmox1 gene did not change
the profile of cytokines and growth factors produced byMSC.
Conditioned media from MSC Hmox1+/+ and Hmox1-/-
contained similar amounts of G-CSF, IL-6, LIF, LIX,
CXCL1, CXCL2, CCL5, and VEGF (Fig. 3D–K). Levels of
eotaxin, GM-CSF, IGNc, IL-1a, IL-1b, IL-2, IL-3, IL-4, IL-
5, IL-7, IL-9, IL-10, IL-12 p40, IL-12 p70, IL-13, IL-15, IL-
17, MIP-1a, MIP-1b, M-CSF, MIP-2, MIG, and TNFa were
under the threshold of detection. Therefore, we concluded
that lack of the Hmox1 gene did not change the tested MSC
secretome and did not affect the ability of MSCs to induce T
cell death both in vitro and in vivo.
Hmox1+/+ and Hmox1-/- MSCs show high resistance
to oxidative stress induced with H2O2 or hemin
Bone marrow-derived proangiogenic cells (BDMC) lack-
ing Hmox1 gene were characterized by higher sensitivity to
oxidative stress, that is, induced with hemin (16). Therefore,
we decided to test whether it is also true for MSCs. Sur-
prisingly, Hmox1+/+ and Hmox1-/- MSCs showed no dif-
ference in the viability when treated for 6 h with H2O2 or
50 lmol/L hemin in both low and high glucose conditions
(Fig. 4A, B). Moreover, treatment with 10 ng/ll of TNFa for
24 h did not yield significant differences in the viability of
MSCs with or without Hmox1 (Supplementary Fig. S3A, B).
FIG. 2. MSC Hmox11/1 or Hmox12/2 show similar ability to differentiate to adipocytes, osteoblasts and smooth
muscle cells. Proliferation of MSC Hmox1+/+ or Hmox1-/- in low or high glucose medium assessed with BrDU assay (A).
Ability to form fibroblastoid (B) or osteoblast (C) colonies by bone marrow cells isolated from Hmox1+/+ or Hmox1-/-
MSCs assessed with fibroblastoid or osteoblast colony-forming unit assay, respectively. Data shown as mean + SD, N = 3.
Expression of Fabp4 in Hmox1+/+ or Hmox1-/- MSCs differentiated to adipocytes in low or high glucose conditions (D)
Gene expression was assessed with qRT-PCR. Data are shown as mean +SD, N = 4–7. Expression of Acta2 (E), Fsp1 (F)
measured with qRT-PCR in control and differentiated MSC Hmox1+/+ or Hmox1-/-. Data are shown as mean – SD,
*p < 0.05, **p < 0.01, ****p < 0.0001 control versus TGFb1; $$p < 0.01 Hmox1+/+ versus Hmox1-/-, N = 3. qRT-PCR,
quantitative real-time PCR.
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Subsequently, we checked the toxic concentrations of hemin
for MSC Hmox1+/+ and Hmox1-/-. Surprisingly, hemin was
more toxic for Hmox1-/- MSCs than for Hmox1+/+ cells not
until at a concentration of 200lmol/L (Fig. 4C). However,
conditioned media from both MSC Hmox1+/+ and Hmox1-/-
showed similar total antioxidant capacity assessed with total
antioxidant capacity (TAC) (Fig. 4D), 2,2¢-azino-bis (3-ethyl-
benzothiazoline-6-sulphonic acid) (ABTS), or ferric-reducing
antioxidant power (FRAP) assays (Supplementary Fig. S3C,
D). The latter result suggests that the reason for the MSC re-
sistance to oxidative stress is rather intrinsic.
First, we supposed that low sensitivity of Hmox1+/+ and
Hmox1-/- MSCs to hemin, especially in comparison to
BDMC, could be related to the high expression of heme
oxygenase-2. However, the expression of Hmox1 was lower
in MSCs Hmox1+/+ than in PACs Hmox1+/+ (Fig. 4E). Si-
milarly, the expression of Hmox2 was lower in MSCs than
in PAC cells and similar in Hmox1+/+ and Hmox1-/- cells
(Fig. 4F). Then, we hypothesized that low sensitivity of
Hmox1-/- MSC cells could be caused by the low uptake of
heme from the culture medium. Therefore, we analyzed heme
uptake with two methods—direct measurement of heme in
cells stimulated for 2 h with 50 lmol/L hemin, and then after
2 h in fresh medium (Fig. 5A), and with the measurement of
tin protoporphyrin IX fluorescence.
Hmox1+/+ andHmox1-/-MSCs displayed comparable levels
of cellular heme at all timepoints tested (Fig. 5B). Moreover,
both cell genotypes showed comparable SnPP fluorescence
proportional to the concentration of SnPP in the culture
medium (Supplementary Fig. S4A). Therefore, higher resis-
tance to hemin in comparison to PAC cannot be explained
by the compensation of Hmox1 function by Hmox2 or by
changed uptake of hemin.
Since bone marrow PACs are mostly of monocytic origin,
and therefore distant from MSCs, we decided to further
focus on the differences in stress response betweenMSCs and
fibroblasts. Interestingly, mouse tail-tip fibroblasts had a
phenotype similar to MSCs, that is, they expressed Sca1,
CD106 and part of them showed positive for CD140a (Sup-
plementary Fig. S5). Both fibroblasts and MSCs, regardless
of Hmox1, were characterized by the similar expression of
heme transporters Hcp1 (Slc46a1) and Hrg1 (Slc48a1)
FIG. 3. Lack of Hmox1 in MSC does not affect their immunomodulatory properties or secretory profile. Number of
circulating CD3+ T cells (A), CD3+AnnexinV+ apoptotic T cells (B), or activated CD3+CD4+CD25high T cells (C) in control
mice or injected i.v. with MSC Hmox1+/+ or Hmox1-/- (N = 3–4). Concentration of G-CSF (D), IL-6 (E), LIF (F), LIX (G),
CXCL1 (H), MCP-1 (I), RANTES (J), and VEGF (K) in conditioned media from Hmox1+/+ or Hmox1-/-MSC assessed
with multiplex assay on Luminex platform. Data are shown as mean –SD, Mann–Whitney, N = 4.
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(Supplementary Fig. S4B, C). MSCs Hmox1-/-were the only
ones to increase in response to hemin treatment and the ex-
pression of heme exporter FLVCR1 (Fig. 5C), which may
protect them from the heme overload.
To further elucidate the effects of heme on MSCs, we
analyzed genes involved in heme synthesis, of which Alas1 is
regulated by heme. Treatment with hemin (50 lmol/L) de-
creased Alas1 expression in all treated cells. Therefore, we
concluded that heme in the culture medium enters treated
cells regardless of Hmox1 expression and affects known
heme-regulated pathways. In Hmox1-/- fibroblasts, already
control cells were characterized by lower Alas1 levels than
Hmox1+/+ cells (Fig. 5D). Expression of Uros in hemin-
treatedHmox1-/- fibroblasts was lower than in corresponding
MSC cells (Supplementary Fig. S4D).
What is more, Hmox1-/- fibroblasts treated with hemin
decreased Cpox expression whereas it remained unchanged
in other cell types (Supplementary Fig. S4E). There were no
differences in the expression of Hmbs, Alad, Ppox, and Fech
(Supplementary Fig. S4E, F). Hmox1 was similarly upregu-
lated in both Hmox1+/+ MSCs and fibroblasts (Fig. 5E). The
expression of Hmox2 was not affected by hemin treatment
and did not differ in any of the tested groups of cells (Fig. 5F).
To sum up, MSCs Hmox1-/- show higher resistance to H2O2
and hemin than previously tested PACs (16). However, low
sensitivity to hemin is not caused by changes in heme uptake
or synthesis and it is not related to Hmox2.
Hemin increases cellular H2O2 in Hmox1
-/-
MSCs and fibroblasts
To assess the effects of hemin on oxidative stress in the
MSCs Hmox1+/+ and Hmox1-/-, we analyzed the levels of
cellular hydrogen peroxide by using H2DCFDA staining. Tail-
tip fibroblasts isolated from the same Hmox1+/+ or Hmox1-/-
micewere used as nonprogenitor internal control cells. After 6 h
of incubation with hemin (50lmol/L), levels of H2O2 were
increased inHmox1-/-MSCs and fibroblasts and higher than in
respective wild-type cells (Fig. 5G). After a 24-h incubation
period, levels of H2O2 remained low inHmox1
+/+ cells andwere
higher in Hmox1-/- fibroblasts than in Hmox1-/- MSCs
(Fig. 5H). This suggests that murine MSCs might be equipped
with an anti-oxidant protective mechanism, which works better
than in fibroblasts.
Nevertheless, after 48 h of stimulation with hemin, both
Hmox1-/- MSCs and Hmox1-/- fibroblasts were dead. Inter-
estingly, at this late timepoint, levels of cellular H2O2 were
higher in hemin-treated Hmox1+/+ fibroblasts than in
FIG. 4. MSC, regardless of the low expression of both heme oxygenases 1 or 2, show high resistance to hemin or
hydrogen peroxide. LDH release in MSC Hmox1+/+ or Hmox1-/- treated with H2O2 (A) or hemin (B) in low or high
glucose medium. Cell death in MSC Hmox1+/+ or Hmox1-/- treated with increasing concentrations of hemin for 6 h,
assessed with 7-AAD staining and flow cytometry (C). Data are shown as mean – SD. ***p < 0.001 two-way ANOVA with
Bonferroni post-test, N = 3. Total antioxidant capacity of conditioned media from MSC Hmox1+/+ or Hmox1-/-, measured
with TAC kit (N= 4) (D). (E) Expression of Hmox1, (F) Hmox2 in murine bone marrow PAC and MSCs isolated from
Hmox1+/+ or Hmox1-/-mice, ****p< 0.0001 MSC versus PAC; two-way ANOVA with Bonferroni post-test, N= 3. 7-AAD,
7-aminoactinomycin D; ANOVA, analysis of variance; LDH, lactate dehydrogenase; PAC, pro-angiogenic cell; TAC, total
antioxidant capacity.
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Hmox1+/+MSCs (Fig. 5I). Therefore, we concluded that both
Hmox1+/+ andHmox1-/-MSC cells showed higher resistance
to hemin than respective tail-tip fibroblasts.
MSCs lacking Hmox1 efficiently induce
antioxidant gene response
A lower concentration of H2O2 in MSC Hmox1
-/- than
Hmox1-/- fibroblasts after short incubation with hemin sug-
gested that MSCs might more effectively respond to the pro-
oxidative insult. Therefore, we evaluated the expression of a
vast panel of antioxidant genes in MSCs and Hmox1+/+ or
Hmox1-/- fibroblasts in response to 50lmol/L hemin. Treat-
ment with hemin did not change the expression of the major
regulator of antioxidant gene response Nfe2l2 (Fig. 6A), which
encodes for the Nrf2 transcription factor. Levels of Sqstm1,
which is both target and regulator of Nrf2 (21), were increased
in MSCs and Hmox1-/- fibroblasts but the upregulation was
higher in MSCs (Fig. 6B).
FIG. 5. Hemin increases intracellular hydrogen peroxide in Hmox11/1 or Hmox12/2 and decreases Alas1 ex-
pression but does not affect levels of heme importers. Scheme of the experiment for the assessment of intracellular heme
content (A). Heme cellular content measured with spectrophotometry in MSC Hmox1+/+ or Hmox1-/- stimulated for 2 h with
hemin (T2) and then after 2 h in hemin-free medium (T4), N = 3 (B). Expression of FLVCR1 (C), Alas1 (D), Hmox1 (E), and
Hmox2 (F) in Hmox1+/+ or Hmox1-/- MSCs or fibroblasts stimulated for 6 h with 50 lmol/L hemin. Levels of H2O2
measured with H2DCFDA after 6 (G), 24 (H), or 48 h (I) in Hmox1
+/+ or Hmox1-/- MSCs or fibroblasts stimulated with
hemin (50lmol/L). Data are shown as mean – SD, *p < 0.05, **p < 0.01, ***p< 0.001, ****p < 0.0001 hemin-treated cells
versus control; ##p < 0.01, ####p < 0.0001 MSC versus fibroblasts, $p < 0.05, $$p< 0.01, $$$p < 0.001, $$$$p < 0.0001 Hmox1+/+
versus Hmox1-/-. Two-way ANOVA with Bonferroni post-test, N = 3.
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FIG. 6. MSC Hmox11/1 show more efficient antioxidant response after treatment with hemin than fibroblasts
Hmox11/1. Expression of Nfe2l2 (A), Sqstm1 (B), Cat (C), Nqo1 (D), Sod2 (E), Sod3 (F), Prdx3 (G), Txn1 (H), Prdx6 (I), Fth1
(J), and Fpn (K) in Hmox1+/+ or Hmox1-/- MSCs or fibroblasts stimulated for 6 h with hemin (50lmol/L). Data are shown as
mean–SD, *p<0.05, **p<0.01, ***p<0.001, ****p< 0.0001 hemin-treated cells versus control; #p<0.05, ##p<0.01,
####p<0.0001 MSC versus fibroblasts, $p < 0.05, $$p < 0.01, $$$p < 0.001, $$$$p < 0.0001 Hmox1+/+ versus Hmox1-/-, Two-
way ANOVA with Bonferroni post-test, N = 3.
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Expression of Cat was the highest in hemin-treated MSC
Hmox1-/-, the only ones to changeCat levels (Fig. 6C). Then,
Hmox1-/- fibroblasts treated with hemin had lower expres-
sion of Nqo1 than Hmox1-/- MSCs, the only cells to upre-
gulate Nqo1 and with its expression higher than Hmox1+/+
MSCs (Fig. 6D). Similarly, expression of Sod2 was changed
only in Hmox1-/- MSC (Fig. 6E) whereas hemin-treated
Hmox1-/- fibroblasts had lower Sod3 levels than corre-
sponding MSC cells (Fig. 6F).
Further, expression of Prdx3 and Txn1 was enhanced with
hemin only in Hmox1-/- MSC cells (Fig. 6G, H); whereas
Prdx4, Prdx5, and Txnrd3 were not affected (Supplementary
Fig. S6A–C). Interestingly, Prdx6, the only 1-Cys member of
peroxiredoxin family (13), was potently upregulated in hemin-
treated Hmox1-/- MSCs. Prdx6 expression was then higher
in MSC Hmox1-/- than in all other cells (Fig. 6I).
MSCs Hmox1-/- were the only ones that upregulated fer-
ritin heavy chain 1 (Fth1) expression in response to the hemin
treatment (Fig. 6J). Levels of Fpn were, on the other hand,
increased only in Hmox1+/+ MSCs (Fig. 6K). Hemin did not
affectNox4 expression in any cells (Supplementary Fig. S6D).
Interestingly, only Hmox1-/- MSCs decreased Gpx1 expres-
sion in response to hemin (Supplementary Fig. S6E), whereas
expression ofGpx3 andGpx4was unchanged (Supplementary
Fig. S6F, G), and expression of Gpx8 was decreased in both
MSC cell types (Supplementary Fig. S6H). On the other hand,
control fibroblasts expressed lower levels of Gpx8 than re-
spective MSCs (Supplementary Fig. S6H).
To summarize, both MSCs and fibroblasts Hmox1-/- up-
regulated Sqstm1 and Prdx6 in response to hemin. Moreover,
the expression of both genes was higher in treated MSC
Hmox1-/- than fibroblasts Hmox1-/-. MSC Hmox1-/- but not
fibroblasts Hmox1-/- elevated levels of transcripts for Cat,
Nqo1, Prdx3, Txn1, and Fth1, which confirmed their more
efficient antioxidant response.
Importantly, MSC Hmox1-/- were the only cells to po-
tently upregulate quintessential genes involved in the glu-
tathione pathway, namely Gclc, Gclm, Gss, and Gsr. MSC
Hmox1-/- also elevated Gstp1 (Fig. 7A–E), which forms a
heterodimer with Prdx6 (13), also increased in hemin-
treated MSC Hmox1-/-. Levels of Gstk1, another glutathi-
one S-transferase, remained unchanged in all cell types
(Fig. 7F). Levels of the upregulated glutathione pathway
genes were higher in hemin-treated Hmox1-/- MSC cells
than in hemin-treated Hmox1+/+ MSCs and Hmox1-/- fi-
broblasts. The latter ones increased expression only ofGclm
and Gstp1 (Fig. 7B, F).
Finally, to functionally validate the unique influence of
hemin on glutathione pathway genes in Hmox1-/- MSCs,
we analyzed reduced glutathione (GSH) to oxidized glu-
tathione (GSSG) ratio, changes in total GSH and GSSG in
MSCs, and fibroblasts of both Hmox1+/+ and Hmox1-/-
phenotypes. Cells were treated with hemin (50 lmol/L)
for 6 h, like in gene expression experiments. However, we
then incubated the cells for two more hours in hemin-free
complete medium to allow for GSH recovery. The GSH/
GSSG ratio that allows assessing cellular oxidative stress
was decreased in both Hmox1+/+ and Hmox1-/- MSCs as
well as in Hmox1-/- fibroblasts. Further, Hmox1-/- fibro-
blasts were characterized by lower GSH/GSSG ratio than
Hmox1-/- MSC cells, which additionally had a slightly
lower ratio than Hmox1+/+ MSCs (Fig. 7G).
Noteworthy, Hmox1-/- MSCs were the only ones that in-
creased total GSH in response to hemin, whereas they caused a
decrease in total GSH inHmox1+/+MSCs (Fig. 7H). Levels of
GSSG were increased in Hmox1+/+ MSCs, Hmox1-/- MSCs,
and Hmox1-/- fibroblasts. They were higher in both Hmox1-/-
cell types than in their respective Hmox1+/+ counterparts.
However, levels of GSSG increased more in Hmox1-/- fibro-
blasts than in Hmox1-/- MSCs (Fig. 7I).
MSCs isolated from Hmox1-/- mice showed, in compari-
son to fibroblasts and PAC, higher resistance to hemin.
However, hemin still increased cellular concentration of
H2O2 in both MSCs and fibroblasts Hmox1
-/-. We show here
for the first time that murine MSCs Hmox1-/- could better
than mouse tail-tip fibroblasts induce antioxidant gene re-
sponse, especially genes involved in the glutathione pathway.
Importantly, changes in the glutathione pathway, observed on
the mRNA level, were further validated functionally by the
measurement of reduced and oxidized cellular glutathione.
One may speculate that such a fast response to stress factors
can, in part, contribute to the presence of only minor effects
of Hmox1 knockout on other functions of murine bone
marrow-derived MSCs.
Discussion
Murine bone marrow-derived MSCs isolated from
Hmox1+/+ or Hmox1-/- mice showed similar phenotype,
proliferation, and differentiation. In our hands, neither pro-
liferation nor differentiation to primary lineages was affected
by increased glucose concentrations in the culture media.
However, we show here for the first time that in comparison
to tail-tip fibroblasts, murine MSCs are more efficient in
antioxidant response.
Available reports on the role of Hmox1 in MSC differen-
tiation are often inconsistent, which may result from the use
of cobalt or tin protoporphyrins to modulate Hmox1 activity
or differences between mouse and human MSCs. Such
species-dependent variations were reported, for example, for
immunomodulatory activities of MSCs, which are regulated
by nitric oxide synthase in murine cells and indoleamine-2,3-
dioxygenase in human cells (51). We performed our experi-
ments on murine bone marrow-derived MSCs isolated from
wild-type or Hmox1-/- mice. Importantly, the unaffected
phenotype of Hmox1-/- MSCs as well as no changes in the
differentiation to adipocytes, osteoblasts, and chondrocytes
were previously shown by Zarjou et al. (66), who also used
cells isolated from Hmox1-/- mice.
On the other hand, Barbagallo et al. reported that expres-
sion of heme oxygenase-1 changes during the differentiation
of human MSCs to osteoblasts (3) and treatment with oste-
ogenic growth peptide increases HMOX1 expression in hu-
man bone marrow MSCs (56). Moreover, human MSCs
stimulated with CoPP during the osteogenic differentiation
had upregulated osteonectin, osteogenic growth peptide, and
osteocalcin. CoPP decreased adipogenic differentiation of
MSCs (3, 56), whereas downregulation of HMOX1 with
siRNA resulted in enhanced adipogenesis.
Human bone marrow MSCs treated with epoxyeicosa-
trienoic acid displayed decreased levels of Bach1, a repressor
of HMOX1 expression (52), and increased HMOX1 mRNA;
whereas levels of PPARc and C/EBPa, involved in adipo-
genesis, were decreased (57). Vanella et al. reported later on
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that inhibition of adipogenesis induced with CoPP and in-
crease with tin mesoporphyrin could be linked to modulation
of the canonical Wnt signaling (59).
Use of hemin, heme oxygenase-1 substrate, and potent
inductor led to the opposite conclusions. Hemin increased
adipogenesis in murine 3T3L1 preadipocytes and human
bone marrow MSCs but also increased oxidative stress and
induced DNA damage in murine preadipocytes (43). Im-
portantly, all observed changes in gene expression induced
with hemin could be reversed with antioxidant Tempol.
Therefore, the authors concluded that oxidative stress is the
key factor that regulates differentiation patterns in hemin-
treated cells (43). Human bone marrow MSCs transduced
with adenoviral vectors encoding for Hmox1 showed no
changes in differentiation pattern but improved viability in
hypoxia (18, 68). However, adenoviral vectors give only
transient expression of the transgene, which was lost after 2
weeks of culture (18).
Primary rat osteoblasts showed reduced expression and
activity of alkaline phosphatase and reduced osteocalcin and
Runx2 expression levels when treated with hemin or when
transduced with adenoviral vectors harboring the Hmox1
FIG. 7. MSC Hmox11/1 strongly induce expression of glutathione pathway enzymes and increase GSH levels after
stimulation with hemin. Expression of Gclc (A), Gclm (B), Gss (C), Gsr (D), Gstp1 (E), and Gstk1 (F) in Hmox1+/+ or
Hmox1-/- MSCs or fibroblasts stimulated for 6 h with hemin (50lmol/L). Ratio of GSH to GSSG (G), changes in total GSH
(H), and GSSG (I) in Hmox1+/+ or Hmox1-/- MSCs and fibroblasts stimulated for 6 h with hemin (50lmol/L) and then kept in
fresh medium for 2 h. Levels of GSH and GSSG were measured with GSH/GSSG-Glo Assay. Data are shown as mean–SD,
*p< 0.05, **p< 0.01, ***p< 0.001, ****p< 0.0001 hemin-treated cells versus control; #p< 0.05, ##p< 0.01, ####p< 0.0001
MSC versus fibroblasts, $p< 0.05, $$p< 0.01, $$$p< 0.001, $$$$p< 0.0001 Hmox1+/+ versus Hmox1-/-, Two-way ANOVA with
Bonferroni post-test, N= 3. GSH, reduced glutathione; GSSG, oxidized glutathione.
120 NOWAK ET AL.
gene (32). Similar results were obtained with carbon mon-
oxide releasing molecule CORM-2 or bilirubin or when
Hmox1 expression was induced with prostaglandin J2
(PGJ2). Effects of hemin or PGJ2 could be reversed with
heme oxygenase-1 inhibitor zinc protoporphyrin (32).
In another study, calcification of human smooth muscle cells
was inhibited when cells were stimulated with heme (65).
Importantly, the effect of heme and heme oxygenase-1 was
mediated by ferritin (65). In our study, MSCs isolated from
Hmox1-/- mice had basal levels of H2O2 similar to those of
wild-type cells and potently elevated Fth1 in response to he-
min. Further, Hmox1-/- MSCs could induce an efficient anti-
oxidant response to hemin, which is a strong stress factor for
cells lacking heme-degrading enzyme. One may speculate that
relatively high resistance to oxidative stress observed in MSC
Hmox1-/- can, at least in part, explain the observed lack of
differences in the pattern of differentiation to basic lineages.
MSC Hmox1+/+ or Hmox1-/- tended to induce T cell ap-
optosis when injected in vivo. However, the change did not
reach statistical significance. Both previous reports analyzing
the role of Hmox1 in immunosuppressive activity of MSCs
used SnPP to inhibit Hmox1 activity (7, 37) and human and
rat (7) or human MSCs (37) and did not assess T cell apo-
ptosis in vivo. Moreover, an in vivo experiment conducted on
the role of Hmox1 in MSCs on the protection from graft
rejection lacked the control group of animals treated with
SnPP only, without MSCs (7). The role played by Hmox1 in
human cells remained ambiguous, since Mougiakakos et al.
failed to show the direct relation between Hmox1 levels and
immunomodulatory activity of MSCs (37).
Surprisingly, both Hmox1+/+ and Hmox1-/- MSCs showed
high resistance to H2O2 or, even more unexpectedly, to
hemin, irrespective of the concentration of glucose in the
medium. Cells devoid of the heme oxygenase-1, enzyme-
degrading heme, were up to now shown to be highly sensitive
to hemin (16). Free heme is toxic to the cells and increases
oxidative stress that may lead to lipid peroxidation, DNA
damage, and protein aggregation [reviewed in (28)].
In our study, we show for the first time that MSCs
Hmox1-/- were resistant to hemin concentrations, which
potently induced cell death in bone marrow PAC cells (16).
Moreover, MSCs Hmox1-/- expressed lower basal levels of
Hmox2 than PAC cells, and Hmox2 remained unaffected by
hemin treatment. Subsequently, Hmox2-dependent heme
degradation cannot be considered a rescue pathway. Finally,
Hmox1+/+ MSCs were characterized by lower Hmox1 levels
than PAC cells and had similar Hmox1 expression in com-
parison to fibroblasts.
We hypothesized that high MSC resistance to hemin could
result from the low import of free heme. Interestingly, heme
uptake in Hmox1+/+ and Hmox1-/- MSCs did not differ. The
latter results were mirrored by the expression of Slc46a1 and
Slc48a1—heme transporters. Expression of Slc48a1 was
shown, however, to be regulated by Bach1 (61), which re-
presses Hmox1 and responds to increased heme concentra-
tion. In our hands, hemin increased expression of heme
exporter FLVCR1 in Hmox1-/- MSCs but not in Hmox1+/+
MSCs or fibroblasts, regardless of their genotype. Increased
FLVCR1 was previously reported in kidneys of Hmox1-/-
mice (48). Therefore, we might speculate that an increase in
FLVCR1 can, at least in part, account for the MSC Hmox1-/-
resistance to hemin.
As expected, hemin decreased expression of 5¢-
aminolevulinate synthase 1 in all tested cell types. Alas1 is a
heme synthesis rate-limiting enzyme, whose levels are tightly
regulated because of the presence of heme regulatory motif in
its promoter (38). Other enzymes involved in the heme syn-
thesis were mostly not changed and did not differ between
Hmox1+/+ and Hmox1-/- cells. Regarding the iron metabo-
lism, hemin-treatedHmox1+/+MSCs upregulated ferroportin.
Fpn expression did not change in MSC Hmox1-/- cells, but
they showed a trend toward higher ferroportin levels than
wild-type controls. On the other hand, Hmox1-/- but not
Hmox1+/+ MSCs or any of fibroblast cells increased ferritin
that captures labile iron and, therefore, protects cells from
oxidative stress [reviewed in (28)].
Although 6 h of treatment with 50lmol/L hemin did not
increase cell death in Hmox1-/- MSCs, it elevated concentra-
tions of cellular hydrogen peroxide. Levels of H2O2 were
higher in Hmox1-/- fibroblasts than in Hmox1-/- MSCs also
after 24 h of treatment with hemin and, importantly, in
Hmox1+/+ fibroblasts than in Hmox1+/+ MSCs after 48 of cul-
ture. However, neither in fibroblasts nor inMSCswe found any
differences in basal levels of H2O2.
Previously, higher H2O2 levels were reported in Hmox1
-/-
than in Hmox1+/+ iPS cells (31). Increased protein carbon-
ylation and lipid peroxidation were also reported in livers and
kidneys of Hmox1-/- mice (42). Basal intracellular ROS
levels in humanMSCs and fibroblasts were similar and lower
than ROS in INS-1 insulinoma (55). Both MSCs and fibro-
blasts were characterized by similar levels of SOD1, SOD2,
CAT, and GPX1mRNA, and higher activities of catalase and
glutathione peroxidase-1 than in INS-1 cells (55). Of note, in
our study, the concentration of hemin, which was toxic for
MSC Hmox1-/- cells, also caused some increase in cell death
in Hmox1+/+ MSCs.
MSCs Hmox1-/- upregulated in response to hemin a set of
genes involved in antioxidant defense, namely Sod2, Prdx3,
Prdx6,Cat,Gclc,Gclm,Gss,Gsr, andGstp1, all of which can
be regulated by the Nrf2 transcription factor. Notably, hemin
induced expression of enzymes involved in both synthesis
and metabolism of glutathione. Bilirubin, which is rapidly
formed by biliverdin reductase from biliverdin, a product of
heme oxygenase activity, is a strong antioxidant (50) that has
properties that are complementary to glutathione (46). Al-
though glutathione has a much higher cellular concentration
than bilirubin, it protects mainly hydrophilic proteins. On the
other hand, lipophilic bilirubin can protect lipids. However, in
our hands, MSC Hmox1-/- cells devoid of heme oxygenase-1
did not change the expression of heme oxygenase-2, another
source of cellular biliverdin.
Increased expression of c-glytamylcysteine ligase and
glutathione synthetase leads to enhanced production of glu-
tathione, whereas upregulated glutathione reductase restores
GSH from GSSG. In our experimental setting, GSH to GSSG
ratio, which is an indication of cell redox status, decreased in
all tested cells treated with hemin. However, the decrease was
much stronger in Hmox1-/- fibroblasts than in Hmox1-/-
MSCs. Hmox1-/- fibroblasts were characterized by higher
total GSSG levels, whereas Hmox1-/-MSCs were the only to
increase total GSH.
Of note, HUVEC cells with long alleles of the HMOX1
promoter, and thus lower levels of HMOX1, treated with H2O2
had higher concentrations of total glutathione and GSSG, but
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lower GSH/GSSG ratio than cells with the short promoter (53).
Further, hemin was shown to induce neuronal necroptosis,
which was related to depletion of glutathione (29).
Increased expression of glutathione metabolism genes in
Hmox1-/- MSCs was accompanied by the upregulation of
peroxiredoxin-6. Prdx6 is the only 1-Cys peroxiredoxin that
uses glutathione instead of thioredoxin, and works as a het-
erodimer with glutathione S-transferase p [reviewed in (13)],
which was also upregulated in hemin-treatedMSCHmox1-/-.
Peroxiredoxin-6 has double activity: peroxidase and phos-
pholipase A2 (13). Interestingly, slightly higher levels of
peroxiredoxin 6 were reported in human MSCs than in em-
bryonic stem cells (22) and both peroxiredoxin-6 and gluta-
thione S-transferase p but also peroxiredoxins 1 and 2
were highly abundant in human MSCs (60).
Expression of peroxiredoxin-6 was not changed in late
passage MSCs in comparison to early passage MSCs, al-
though aged and more senescent cells showed increased
H2O2 concentration (19). In another study, aged MSCs were
characterized rather by increased peroxiredoxin 5 expression
(24). Surprisingly, hemin treatment, which is used to induce
erythroid differentiation of K562 erythroleukemia cells, de-
creased peroxiredoxin-6 levels in K562 cells (25).
We put forward that increased expression of peroxiredoxin
6 and other antioxidant genes should be rather considered as a
protective mechanism that allows cells to deal better with
oxidative stress than BDMC (Supplementary Fig. S7). Al-
though levels of H2O2 in fibroblasts and MSCs were similar,
only the latter cells were able to upregulate peroxiredoxin 6
and its partner—glutathione S-transferase p.
MSCs isolated from Hmox1-/- mice were able to react to
oxidative stress better than fibroblasts and recovered gluta-
thione faster. One may speculate that MSCs can express
lower levels of Keap1 or Nrf3, both of which can decrease
activity of Nrf2 transcription factor. Nevertheless, our data
show that cells such as MSCs are better equipped with the
measures to deal with harsh conditions than other bone
marrow-derived cells, especially proangiogenic cells. Fur-
ther, we can speculate that certain cell types are less depen-
dent on heme oxygenase-1, which is considered a crucial
cytoprotective enzyme. Tested functions and differentiation




All procedures involving the use of animals were per-
formed according to approved guidelines. Mice were main-
tained under the specific pathogen-free conditions, in
individually ventilated cages, with full access to food and
water. All animal experiments were approved by the Local
Ethical Committee for Animal Research at the Jagiellonian
University.
Isolation of MSCs
MSCs were isolated from femurs and tibia of C57Bl6·FVB
Hmox1+/+ or C57Bl6·FVB Hmox1-/-. Mice were sacrificed
with the overdose of ketamine/xylazine. Bones were resected
under the sterile laminar flow hood and cut into small pieces
(ca. 1mm2) with a bone cutter. Then, bone chips were digested
with 1mg/mL type II collagenase (Gibco) for 90–120min in
37C in a rotary shaker (250 rpm). Released cells were washed
once with PBS and resuspended in the growthmedium [aMEM
supplemented with 10% FBS (Lonza) and penicillin with
streptomycin (Sigma-Aldrich, St. Louis, MO)].
Cells were seeded in six-well plates—bone marrow from
one mouse per well. The medium was changed every 24 h in
the first 3 days and every 2–3 days after that, and cells were
passaged when confluent. Importantly, before the MACS
sorting, cells were detached with short treatment with trypsin
(2min; Gibco) at room temperature to decrease the number of
highly adherent macrophages in culture. After three passages,
MSCs were further purified from the CD45+ fraction with
MACS sorting.
MACS sorting of CD45- murine bone marrow
stromal cells
Bone marrow-derived cells were detached with trypsin,
washed with PBS, resuspended in AutoMACS running buffer
(Miltenyi), and stained for 25min with anti-mouse CD45
MicroBeads (Miltenyi) in 4C. Then, the cells were washed
with 1mL of PBS, resuspended in AutoMACS Running
Buffer, and separated on MACS MS columns (Miltenyi) or
with AutoMACS (Miltenyi). Flow-through with CD45- cells
was collected, and columns with CD45+ cells were discarded.
Purified CD45- murine bone marrow MSCs were next
counted and either used directly for the experiments or see-
ded for further culture (1.5–2.0 · 104/1 cm2) in aMEM
complete medium (CM).
Isolation of murine fibroblasts
Murine adult tail fibroblasts were isolated from C57Bl6 ·
FVB Hmox1+/+ or C57Bl6 · FVB Hmox1-/- according to the
previously published protocol (49) and cultured in DMEM
(Lonza) medium supplemented with 10% FBS (Lonza) and
penicillin with streptomycin (Sigma-Aldrich).
Isolation of murine bone marrow PAC
Murine bone marrow proangiogenic cells were isolated as
described earlier (14, 16) and cultured in EGM2-MVmedium
(Lonza) with 10% FBS and penicillin with streptomycin
(Sigma-Aldrich).
Analysis of fibroblast- or osteoblast
colony-forming units
Cells isolated from the bone marrow were counted by
using Tu¨rck solution (Merck) to lyse red blood cells. Then,
1 · 106 of bone marrow cells were seeded per well in six-well
plates. Cells were cultured until colonies of fibroblastoid cells
were formed. At that stage, part of the wells was fixed and
stained with crystal violet and the colonies of fibroblastoid
cells were counted. Another part of the cells was treated with
osteogenic differentiation medium for the next 3 weeks, and
then cells were stained with Alizarin Red S and positive
colonies were counted.
MSCs phenotyping
MSCs cultured for three passages after the isolation were
detached with trypsin, washed with PBS, and stained for
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25min in AutoMACS Running Buffer at 4C with the fol-
lowing antibodies: anti-mouse CD45 (clone 30F-11; BD
Biosciences), anti-mouse CD29 (clone HMb1-1; BioLegend),
anti-mouse CD31 (clone MEC13.3; BD Biosciences), anti-
mouse CD34 (clone RAM34; BD Biosciences), anti-mouse
CD90.2 (clone 30-H12; BioLegend), anti-mouse CD105
(clone MJ7/18; BioLegend), anti-mouse CD117 (c-kit) (clone
2B8; eBioscience), anti-mouse CD140a (clone APA5;
eBioscience), and anti-mouse Ly-6A/E (Sca-1) (clone D7;
eBioscience). The phenotype of the cells was assessed with
BD LSR II or BD LSR Fortessa (Becton Dickinson).
MSCs: differentiation to osteoblasts
MSCs Hmox1+/+ or Hmox1-/- were differentiated to oste-
oblasts with the protocol by Zhu et al. (69). Briefly, 2.5 · 104
of sorted CD45- bonemarrow stromal cells were seeded per 1
well of 24-well plates. Osteoblast differentiation was induced
for 3 weeks with aMEM CM supplemented with 0.1 lmol/L
dexamethasone, 10mmol/L b-glycerol phosphate, and
50 lmol/L ascorbate-2-phosphate (all from Sigma-Aldrich)
and verified with AlizarinRed S staining (Supplementary
Fig. S1A), gene expression analysis, and immunofluorescent
staining for osteopontin (clone EPR3688; Abcam). Control
cells were cultured in aMEM CM. Low glucose differentia-
tion or control medium contained 5mmol/L glucose, and
high glucose differentiation or control medium contained
33mmol/L glucose.
MSCs: differentiation to adipocytes
MSCs Hmox1+/+ or Hmox1-/- were differentiated to adi-
pocytes with the protocol by Zhu et al. (69). Briefly, 2.5 · 104
of sorted CD45- bonemarrow stromal cells were seeded per 1
well of 24-well plates. Adipocyte differentiation was induced
for 3 weeks with aMEM CM supplemented with 1.0 lmol/L
dexamethasone, 50lmol/L 3-isobutyl-1-methylxanthine
(IBMX), and 10 ng/mL insulin (all from Sigma-Aldrich) and
verified with OilRedO staining, gene expression analysis, and
immunofluorescent staining for Fabp4 (clone EPR3579;
Abcam). Control cells were cultured in aMEM CM. Low
glucose differentiation or control medium contained 5mmol/
L glucose, and high glucose differentiation or control me-
dium contained 33mmol/L glucose.
MSCs: differentiation to myofibroblasts
Sorted CD45- bone marrow stromal cells were seeded in
24-well plates (2.5 · 104/well). Myofibroblast differentiation
was induced for 6 days with aMEM CM supplemented with
2 ng/mL recombinant human TGFb1 (Peprotech) and con-
firmed with gene expression analysis. Control cells were
cultured in aMEM CM.
Analysis of MSC immunosuppressive activity in vivo
C57Bl6 · FVB mice were injected intravenously with 1
million of MSC Hmox1+/+ or Hmox1-/-, or saline (vehicle
control) and sacrificed 24h later. Numbers of circulating CD3+
T cells, CD3+AnnexinV+ apoptotic T cells, and CD3+CD4+
CD25high activated T cells were assessed by flow cytometry on
an LSR Fortessa cytometer (Becton Dickinson). Peripheral
blood (PB) was collected in heparinized tubes. Red blood cells
were lysed with ammonium chloride red blood cell lysis buffer
(0.15M NH4Cl, 10mM KHCO3, 0.1mM EDTA). Obtained
total nucleated cells were resuspended in autoMACS Running
Buffer (Miltenyi).
Cells were then stained with anti-mouse CD3 (clone 17A2;
BDHorizon), anti-mouse CD4 (clone RPA-T4; BDHorizon),
anti-mouse CD25 (clone C37; BD Pharmingen), and anti-
mouse CD45 (clone 30-F11; BD Pharmingen) antibodies.
Annexin V+ cells were stained with TACS Annexin V
(AnV) kit (Trevigen) according to the manufacturer’s in-
structions. The number of cells per 1lL of PB was calculated
based on the total leukocyte count (WBC, 103 cells/1 lL of
PB) and the percentage of each population within the col-
lected events. WBC was measured by using ABC Vet (scil
animal care GmbH).
Analysis of MSC immunosuppressive activity in vitro
MSC Hmox1+/+ or Hmox1-/- were seeded on six-well
plates. When MSCs reached 100% confluency, they were co-
cultured for 24 h with 1 mln of primary mouse splenocytes in
each well. After the co-culture, splenocytes were harvested
and stained with anti-CD3-AlexaFluor 647 (clone 17A2; BD
Pharmingen), anti-Ki67-AlexaFluor 488 (clone B56; BD
Pharmingen), and DAPI for the analysis of cell proliferation
or with anti-CD3-AlexaFluor 647 (clone 17A2; BD Phar-
mingen), and Anexin V-FITC (Trevigen) for the analysis of T
cell apoptosis. Data are presented as percent of proliferating/
apoptotic T cells within the population of CD3+ T cells.
Total antioxidant capacity assays
Total antioxidant capacity of conditioned media from
MSC Hmox1+/+ or Hmox1-/- was measured with TAC Assay
(Cell Biolabs) according to the manufacturer’s protocol, or
using ABTS, or FRAP method. ABTS assay was performed
according to the previously published protocol (40) based on
the (12) method. FRAP assay was based on the Benzie and
Strain method (4).
Multiplex immunoassays
Levels of factors produced byMSCHmox1+/+ orHmox1-/-
were measured with Milliplex MAP Mouse Cytokine/
Chemokine Bead Panel -32 Plex (Millipore) on Luminex
FlexMap 3D platform (Millipore) and analyzed with Milli-
plex Analyst 3.4 software (Millipore).
Proliferation assay
The proliferation of MSCs was assessed with the BrdU
method by using Cell Proliferation ELISA (Roche), accord-
ing to the manufacturer’s protocol. Low glucose medium
contained 5mmol/L glucose, and high glucose medium
contained 33mmol/L glucose. Cells were cultured in high or
low glucose medium and BrdU labeling solution for 24 h.
Lactate dehydrogenase activity assay
Cytotoxicity of hemin or H2O2 inMSCs was evaluated with
CytoTox 96 NonRadioactive Cytotoxicity Assay (Promega),
according to the manufacturer’s protocol. Low glucose me-
dium contained 5mmol/L glucose, and high glucose medium
contained 33mmol/L glucose. Cells were treated with hemin,
H2O2, and/or high glucose for 6 h before the analysis.
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7-aminoactinomycin D-based cell viability assay
The viability of MSCs stimulated for 6 h with high doses
of hemin was assessed by 7-aminoactinomycin D (7-AAD)
staining. Stimulated and control cells were detached with
trypsin, washed with PBS, and resuspended in AutoMACS
Running Buffer (Miltenyi). Then, cells were stained for
10min with 7-AAD (BD Pharmingen) according to the
manufacturer’s protocol and analyzed on a BD LSR Fortessa
cytometer.
Measurement of MSC viability in response to TNFa
MSCHmox1+/+ orHmox1-/-were incubated with 10ng/mL
TNFa for 24 h. Then, numbers of early and late apoptotic
cells were assessed by flow cytometry by using the staining
with Hoechst 33342 and 7-AAD according to the protocol by
Schmid et al. (45).
Measurement of cellular H2O2 levels
Levels of cellular H2O2 were measured with H2DCFDA
assay. Hmox1+/+ or Hmox1-/- MSCs and fibroblasts were
stimulated for 6, 24, or 48 h with 50 lmol/L hemin (Frontiers
Scientific). After each timepoint, the stimulated cells and
nonstimulated controls were harvested with trypsin, washed
with PBS, and stained for 30min with 0.1 lmol/L H2DCFDA
(Sigma-Aldrich) in PBS. Then, cells were washed twice with
PBS, and DCFDA fluorescence was assessed with a BD LSR
Fortessa cytometer (Becton Dickinson).
Heme cellular content assay
MSCs Hmox1+/+ or Hmox1-/- were cultured in 24-well
plates. Heme content was assessed with the method by For-
esti et al. (15) in nonstimulated cells (T0), after 2 h of stim-
ulation with 50 lmol/L hemin (T2) and after 2 additional
hours of culture in fresh aMEM CM (T4). Cells were lysed
with 80% formic acid (POCH S.A.), and the lysate was
transferred to clear plastic 96-well plates. Absorbance was
measured at l = 398 nm with a GENios microplate reader
(Tecan).
SnPP binding assay
Cells stimulated with SnPP (Frontiers Scientific) show
fluorescence in APC channel (lex = 640 nm, emission de-
tected with 670/25 bandpass filter). Therefore, we stimulated
Hmox1+/+ and Hmox1-/- MSCs with 10, 25, or 50 lmol/L
SnPP for 6 h and analyzed their fluorescence with flow cy-
tometry. Cells were detached with trypsin, washed, and re-
suspended in AutoMACS Running Buffer (Miltenyi). Flow
cytometry analysis was performed on a BD LSR Fortessa
cytometer (Becton Dickinson).
GSH/GSSG assay
Levels of total GSH, total GSSG, and GSH/GSSG ratio in
MSCs and fibroblasts were assessed with GSH/GSSG-Glo
Assay (Promega) according to the manufacturer’s protocol.
Then, 1.0 · 104 cells were seeded per well in 96-well plates.
Cells were stimulated for 4 h with 50lmol/L hemin in aMEM
CM and cultured for 2 h in aMEM CM to let them recover
GSH levels. Total GSH and total GSSG data are shown as a
ratio to the control nonstimulated cells.
Analysis of gene expression
Total RNA was isolated by phenol-chloroform extraction,
and it was reverse transcribed with the oligo(dT) primers and
RevertAid Reverse transcriptase (Fermentas) or with the
NCode VILO miRNA cDNA synthesis kit (Invitrogen).
The expression of genes was assessed by quantitative real-
time PCR (qRT-PCR), which was performed in the StepO-
nePlus system (Applied Biosystems, Foster City, CA) with
the specific primers (Supplementary Tables S1 and S2),
cDNA and SYBR Green Quantitative RT-PCR kit (Sigma-
Aldrich), under conditions summarized in Supplementary
Table S3.
Expression of lipid metabolism genes in Hmox1+/+ or
Hmox1-/- MSCs differentiated to adipocytes was assessed
with TaqMan Array Mouse Lipid-Regulated Genes (Ap-
plied Biosystems) and TaqMan Universal PCR Master Mix
(Applied Biosystems) with the PCR program described in
Supplementary Table S3.
Statistical analysis
Statistical analysis of the data was performed with
GraphPad Prism software. Results are expressed as mean –
SD unless otherwise stated. Statistical significance was ac-
cepted at p< 0.05. Data obtained in in vitro experiments were
analyzed with Student’s t-test when two groups of samples
were used. In another case, we used one-way or two-way
analysis of variance with Bonferroni post-test. The kind of
statistical test applied to analyze given sets of data is provided
in the description of figures.
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BDMC¼ bone marrow-derived proangiogenic
cells
CM¼ complete medium
CoPP¼ cobalt protoporphyrin IX
FRAP¼ ferric-reducing antioxidant power
GSH¼ reduced glutathione
GSSG¼ oxidized glutathione






qRT-PCR¼ quantitative real-time PCR
SnPP¼ tin protoporphyrin IX
TAC¼ total antioxidant capacity
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